YD Global Life Science focuses on innovative drug development, particularly in the fields of chemical informatics, bioinformatics, and gene therapy. The company employs a robust platform that integrates a compound library and experimental data to enhance its research capabilities. This platform allows for the utilization of fragment databases, which facilitate the identification and optimization of potential drug candidates. By leveraging these technologies, YD Global Life Science aims to streamline the drug discovery process and improve the efficacy of its therapeutic offerings.

One of the key products in YD Global Life Science's pipeline is YD312, a first-in-class oral medication targeting the c-Kit receptor, which is implicated in various retinal vascular diseases. This drug is designed to inhibit the mechanisms that lead to abnormal blood vessel growth and leakage, conditions often associated with diabetes and age-related macular degeneration. The development of YD312 not only presents a promising alternative to existing injectable therapies but also aims to enhance patient compliance through its convenient oral administration. The company is committed to advancing its pipeline, which includes several other candidates targeting conditions in ophthalmology and oncology.

South Korea

YDGLS develops new drugs for various diseases and development & sales of precision medical products & apparatus and healthcare products.

Cancer

Endocrine System Diseases

Eye Diseases

Lung Diseases

Nervous System Diseases

YD Global Life Science

Age-related macular degeneration

Diabetic macular edema

Diabetic retinopathy

YD312

Small Molecule Pharmaceuticals

Interstitial lung disease

Lung fibrosis

YDC105

Alzheimer's disease

YDC103,YDC104

Solid tumor/s

YDB102,YDB201

Biologics

Gene Therapy

YDC101

Bioinformatics

Therapeutic

YD Global Life Science

Company Details